Company Details
- Employees
- 45
- Founded
- -
- Address
- 12747 Olive Bouldvard,
- Phone
- 314.878.3500
- in****@****.us.com
- Industry
- Architecture And Planning
- NAICS
-
Architectural Services
- Website
- mha.us.com
- HQ
- St. Louis, MO
Please complete the CAPTCHA to continue
Related company profiles:
Consumer confidence dips as markets rally The Real Economy Blog
The Association Between Cytomegalovirus Infection and Increased Leukemia Incidence: A Retrospective Matched Cohort Cureus
Daily Digest: Top news from October 28 Insurance Insider US
Stripped Shelby GT500 Sits as a Hollow Reminder of Stolen Muscle Car Tragedy Motorious
Nobuhiro Hosoki Cinema Daily US
EY US - Home | Building a better working world EY
Driving change: The new roadmap for automotive retail transformation RSM
FM appoints Liberty Mutual’s Erbig as new CFO Insurance Insider US
Isolated Ruptured Pulmonary Hydatid Cyst Mimicking Community-Acquired Pneumonia Cureus
Massive Nationwide Cancer Charity Fraud Scheme Serves as Warning Oncology News Central
AstraZeneca Foundation awards over $1.4M in third year grants to advance healthcare access; announces 2026 call for applications AstraZeneca US
American Rheinmetall Munitions and Solugen to formalize partnership Rheinmetall
Holly Starks Acquires the Flumberico Brand, Expanding the Vision Behind flumberico.us.com Yahoo Finance
Higher cedant retention on property cat a headwind for reinsurance: Arch CEO Insurance Insider US
AdvaMed Code of Ethics® AdvaMed® - Advanced Medical Technology Association®
Market Minute: Falling bond yields and economic imbalances The Real Economy Blog
BofA Launches ‘Golf with Us’ to Bring Affordable Rounds to More Than 50,000 Youth Nationwide Bank of America
Car donation charity fined millions, accepts fundraising restrictions in Colorado and 18 other states CBS News
U.S.A. Home Hitachi Global
FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery AstraZeneca US
Empowering Action in Asthma Care This Season and Beyond AstraZeneca US
iPR Pharmaceuticals Earns its 1st EPA’s ENERGY STAR® Certification for Superior Energy Efficiency AstraZeneca US
AstraZeneca impact in the US AstraZeneca US
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer AstraZeneca US
Our impact, our people AstraZeneca US
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D AstraZeneca US
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial AstraZeneca US
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 AstraZeneca US
Celebrating National Nonprofit Day: Partnerships That Transform Healthcare Access AstraZeneca US
AIRSUPRA ® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol AstraZeneca US
Delaware AG joins lawsuit against 'deceptive' breast cancer fundraising operation Delawareonline.com
CONSUMER PROTECTION NEWS: FTC, 19... VitalLaw.com
Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis AstraZeneca US
Nationwide Fake Cancer Charity Scam Busted, Kars-R-Us.com Inc. Accused Hoodline
Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalized myasthenia gravis in PREVAIL Phase III trial AstraZeneca US
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma AstraZeneca US
Partnerships in Motion: How Cross-Sector Collaboration is Powering Broader Clinical Trial Representation AstraZeneca US
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial AstraZeneca US
Trump calls for using US cities as a ‘training ground’ for military in unusual speech to generals Federal News Network
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial AstraZeneca US
Be careful with online Joann closure sales Canton Repository
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer AstraZeneca US
Luv n' care Recalls Nuby Stroller Fans Due to Laceration Injury Hazard U.S. Consumer Product Safety Commission (.gov)
American Rheinmetall secures order for T-158 tracks Rheinmetall
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial AstraZeneca US
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer AstraZeneca US
Announcing the 2024 Power of Us Award winners AstraZeneca US
FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity PR Newswire
US Com Sec Lutnick says again on tariffs that 10 is baseline, no one’s going below 10 TradingView
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial AstraZeneca US
Rheinmetall completes acquisition of Loc Performance in the USA Rheinmetall
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer AstraZeneca US
Announcing the 2024-2025 US ACT on Health Equity Community Investments Recipients AstraZeneca US
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca US
Collective Action to Advance Health Equity AstraZeneca US
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis AstraZeneca US
What science can do AstraZeneca US
Affordability AstraZeneca US
AIRSUPRA (PT027) approved in the US for asthma AstraZeneca US
Announcing the 2023 Power of Us Award winners AstraZeneca US
Scot Anderson Womble Bond Dickinson
The Real Economy: October 2025 RSM
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) AstraZeneca US
Tracy A. Bacigalupo Womble Bond Dickinson
Investigator Sponsored Studies (ISS) Program Novo Nordisk U.S. Website
TEZSPIRE approved for self-administration in the US with a new pre-filled pen AstraZeneca US
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial AstraZeneca US
Who We Are Otsuka US
FluMist approved for self-administration in the US AstraZeneca US
Careers AstraZeneca US
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial AstraZeneca US
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer AstraZeneca US
WAINUA (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis AstraZeneca US
Nonprofit and education RSM
ispace-US and Rhea Space Activity Sign Payload Services Agreement Aimed at Expanding Deep Space Technological Capabilities ispace
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH AstraZeneca US
Contact Us AstraZeneca US
ispace - U.S. Announces new U.S. Headquarters, Unveils APEX 1.0 Lunar Lander, Provides Updates on Mission 3 ispace
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer AstraZeneca US
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery AstraZeneca US
Product patents Novo Nordisk U.S. Website
Alexander P. Wharton Womble Bond Dickinson
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer AstraZeneca US
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients AstraZeneca US
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer AstraZeneca US
Portraits of Lung Cancer AstraZeneca US
ispace-U.S. Accelerates its Mission 3 Utilizing Agile Development with Fusion by Stoke Space ispace
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma AstraZeneca US
Agreement to takeover US vehicle specialist Loc Performance Rheinmetall
SAPHNELO (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus AstraZeneca US
BYDUREON BCise (exenatide extended-release) approved in the US for the treatment of type 2 diabetes in pediatric patients ages 10 years and older AstraZeneca US
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer AstraZeneca US
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors AstraZeneca US
Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma AstraZeneca US
FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) Vaccine Now Available in the US for Annual Flu Season AstraZeneca US
AstraZeneca’s Aradhana Sarin Named to CNBC’s 2024 Changemakers: Women Transforming Business List AstraZeneca US
LYNPARZA® (olaparib) approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer AstraZeneca US
PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma AstraZeneca US
Personified: Bridget Therriault AstraZeneca US
2 +163644XXXXX
4 +131487XXXXX
3 +131484XXXXX
2 +131487XXXXX
Find emails, phones & company data instantly
Your AI prospecting assistant
0 records × $0.02 per record
Secure checkout
Total price
$0.50
Enter your payment details below to complete the download. We'll email you the CSV as soon as it's ready.
Processing your payment...
Please wait while we complete your transaction
Sign in required
Create a free account or sign in to continue downloading the full results.
Sign up for a free account. No credit card required. Up to 10 free credits.
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.